ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

Video

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

Recent Videos
A panel of 3 experts on CML
Related Content
Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

Pembrolizumab/Cisplatin Combo Shows Promise in Small Cell Bladder Cancer, Neuroendocrine Prostate Cancer

Tim Cortese
November 18th 2024
Article

Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.

Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status

Russ Conroy
October 29th 2024
Article

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.

Emerging Immunotherapy Approaches For Urothelial Cancer

Emerging Immunotherapy Approaches For Urothelial Cancer

Petros Grivas, MD, PhD
February 4th 2019
Podcast

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

TAS-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

TAR-200 Study in Muscle-Invasive Bladder Cancer Discontinued

Ariana Pelosci
October 9th 2024
Article

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.

Enfortumab Vedotin Combo Earns Japanese Approval for Urothelial Carcinoma

Roman Fabbricatore
September 24th 2024
Article

Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.